Oral tolerance inhibits atopic dermatitis-like type 2 inflammation in mice by modulating immune microenvironments

Allergy ◽  
2016 ◽  
Vol 72 (3) ◽  
pp. 397-406 ◽  
Author(s):  
J.O. Baek ◽  
J.Y. Roh ◽  
Y. Jung
Keyword(s):  
Atopic Dermatitis ◽  
Oral Tolerance ◽  
Type 2 Inflammation

Prednisolone Treatment Reduces Type 2 Inflammation In Skin Lesions Of Patients With Atopic Dermatitis

2021 ◽  
Vol 147 (2) ◽  
pp. AB35
Author(s):  
Emma Price ◽  
Christiane Whetstone ◽  
Dhuha Al-Sajee ◽  
Sai Sakktee Krisna ◽  
Karen Howie ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Skin Lesions ◽  
Prednisolone Treatment ◽  
Type 2 Inflammation

scholarly journals The Pathology of Type 2 Inflammation-Associated Itch in Atopic Dermatitis

Diagnostics ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 2090
Author(s):  
Catharina Sagita Moniaga ◽  
Mitsutoshi Tominaga ◽  
Kenji Takamori
Keyword(s):  
Clinical Trials ◽  
Atopic Dermatitis ◽  
Biologic Agents ◽  
Comprehensive Understanding ◽  
Nervous Systems ◽  
Neuroimmune Interactions ◽  
Advanced Stages ◽  
Type 2 Inflammation

Accumulated evidence on type 2 inflammation-associated itch in atopic dermatitis has recently been reported. Crosstalk between the immune and nervous systems (neuroimmune interactions) is prominent in atopic dermatitis research, particularly regarding itch and inflammation. A comprehensive understanding of bidirectional neuroimmune interactions will provide insights into the pathogenesis of itch and its treatment. There is currently no agreed cure for itch in atopic dermatitis; however, increasing numbers of novel and targeted biologic agents have potential for its management and are in the advanced stages of clinical trials. In this review, we summarize and discuss advances in our understanding of type 2 inflammation-associated itch and implications for its management and treatment in patients with atopic dermatitis.

Prominent Role of Type 2 Immunity in Skin Diseases—Beyond Atopic Dermatitis

2021 ◽  
pp. 120347542110278
Author(s):  
Lina Belmesk ◽  
Anastasiya Muntyanu ◽  
Emmanuelle Cantin ◽  
Zeinah AlHalees ◽  
Carolyn S. Jack ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Cancer Progression ◽  
Skin Diseases ◽  
Skin Neoplasms ◽  
Lymphoid Cells ◽  
Type 2 Immunity ◽  
Group 2 ◽  
Type 2 Inflammation

Type 2 immunity, illustrated by T helper 2 lymphocytes (Th2) and downstream cytokines (IL-4, IL-13, IL-31) as well as group 2 innate lymphoid cells (ILC2), is important in host defense and wound healing. 1 The hallmark of type 2 inflammation is eosinophilia and/or high IgE counts and is best recognized in atopic diathesis. Persistent eosinophilia, such as seen in hypereosinophilic syndromes, leads to fibrosis and hence therapeutic Type 2 inhibition in fibrotic diseases is of high interest. Furthermore, as demonstrated in cutaneous T cell lymphoma, advanced disease is characterized by Th1 to Th2 switch allowing cancer progression and immunosuppression. Development of targeted monoclonal antibodies against IL-4Rα (eg, dupilumab) led to a paradigm shift for the treatment of atopic dermatitis (AD) and stimulated research to better understand the role of Type 2 inflammation in other skin conditions. In this review, we summarize up to date knowledge on the role of Type 2 inflammation in skin diseases other than AD and highlight whether the use of Type 2 targeted therapies has been documented or is being investigated in clinical trials. This manuscript reviews the role of Type 2 inflammation in dermatitis, neurodermatitis, IgE-mediated dermatoses (eg, bullous pemphigoid, chronic spontaneous urticaria), sclerodermoid conditions and skin neoplasms.

scholarly journals Pathological Roles and Clinical Usefulness of Periostin in Type 2 Inflammation and Pulmonary Fibrosis

Biomolecules ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1084
Author(s):  
Junya Ono ◽  
Masayuki Takai ◽  
Ayami Kamei ◽  
Yoshinori Azuma ◽  
Kenji Izuhara
Keyword(s):  
Pulmonary Fibrosis ◽  
Transforming Growth Factor ◽  
Biological Fluids ◽  
Allergic Inflammation ◽  
Transforming Growth Factor Β ◽  
Serum Levels ◽  
Vital Role ◽  
Interleukin 4 ◽  
Type 2 Inflammation

Periostin is known to be a useful biomarker for various diseases. In this article, we focus on allergic diseases and pulmonary fibrosis, for which we and others are now developing detection systems for periostin as a biomarker. Biomarker-based precision medicine in the management of type 2 inflammation and fibrotic diseases since heterogeneity is of utmost importance. Periostin expression is induced by type 2 cytokines (interleukin-4/-13) or transforming growth factor-β, and plays a vital role in the pathogenesis of allergic inflammation or interstitial lung disease, respectively, andits serum levels are correlated disease severity, prognosis and responsiveness to the treatment. We first summarise the importance of type 2 biomarker and then describe the pathological role of periostin in the development and progression of type 2 allergic inflammation and pulmonary fibrosis. In addition, then, we summarise the recent development of assay methods for periostin detection, and analyse the diseases in which periostin concentration is elevated in serum and local biological fluids and its usefulness as a biomarker. Furthermore, we describe recent findings of periostin as a biomarker in the use of biologics or anti-fibrotic therapy. Finally, we describe the factors that influence the change in periostin concentration under the healthy conditions.

Lung function fluctuation patterns unveil asthma and COPD phenotypes unrelated to type 2 inflammation

2021 ◽  
Author(s):  
Edgar Delgado-Eckert ◽  
Anna James ◽  
Delphine Meier-Girard ◽  
Maciej Kupczyk ◽  
Lars I. Andersson ◽  
...  
Keyword(s):  
Lung Function ◽  
Type 2 Inflammation ◽  
Function Fluctuation
Sign in / Sign up

Export Citation Format

Share Document